On June 5, 2019 Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, reported that the company will host a conference call to discuss the co-development agreement with Pfizer and Merck KGaA (Press release, Oncolytics Biotech, JUN 5, 2019, https://ir.oncolyticsbiotech.com/news/detail/461/oncolytics-biotech-r-to-host-conference-call-to-discuss-co-development-agreement-with-pfizer-and-merck-kgaa [SID1234536902]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Webcast and Conference Call
Oncolytics management will host a conference call with a question and answer session for Analysts and Institutional Investors today, Wednesday, June 5, 2019 at 8:30 am ET. The live call may be accessed by dialing 877-407-9205 for callers in North America. A replay of this call will be available approximately two hours after the call is ended at 877-481-4010 for North American callers and 919-882-2331 for overseas callers using the replay code 49448 and will be available for one week. A live audio webcast of the call will be accessible on the Investor Relations page of Oncolytics’ website at www.oncolyticsbiotech.com and will be archived for three months.
International callers can access the live call at the following numbers:
Netherlands: 0 800 023 4340 (toll free)
United Kingdom: 0 800 756 3429 (toll free)
Switzerland: 0 800 835 525 (toll free)
Others: +1 201-689-8054